Market Chatter: Novo Holdings to Win EU Approval for $16.5 Billion Catalent Takeover

MT Newswires Live11-25 20:53

Novo Nordisk's (NVO) parent company, Novo Holdings, is expected to win EU antitrust approval for its pending $16.5 billion acquisition of US contract drug maker Catalent (CTLT), Reuters reported Friday, citing an unnamed person with direct knowledge of the matter.

The report said that Catalent is preparing senior management for the deal to go through.

The deal, crucial for boosting production of Novo Nordisk's blockbuster weight-loss drug Wegovy, awaits a final decision from the European Commission by Dec. 6.

Novo Nordisk, Catalent, European Commission did not immediately respond to requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486086997?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-25 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486086997","market":"hk","top_or_hot":-1,"title":"Market Chatter: Novo Holdings to Win EU Approval for $16.5 Billion Catalent Takeover","media":"MT Newswires Live","content":"<html><body><p> Novo Nordisk's (NVO) parent company, Novo Holdings, is expected to win EU antitrust approval for its pending $16.5 billion acquisition of US contract drug maker <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> (CTLT), Reuters reported Friday, citing an unnamed person with direct knowledge of the matter.</p><p>The report said that Catalent is preparing senior management for the deal to go through.</p><p>The deal, crucial for boosting production of Novo Nordisk's blockbuster weight-loss drug Wegovy, awaits a final decision from the European Commission by Dec. 6.</p><p>Novo Nordisk, Catalent, European Commission did not immediately respond to requests for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Novo Holdings to Win EU Approval for $16.5 Billion Catalent Takeover</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Novo Holdings to Win EU Approval for $16.5 Billion Catalent Takeover\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 20:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk's (NVO) parent company, Novo Holdings, is expected to win EU antitrust approval for its pending $16.5 billion acquisition of US contract drug maker Catalent (CTLT), Reuters reported ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154236417.USD","symbol_name":"BGF US FLEXIBLE EQUITY \"A2\" ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486086997","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486086997","pubTimestamp":1732539182,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk's  parent company, Novo Holdings, is expected to win EU antitrust approval for its pending $16.5 billion acquisition of US contract drug maker Catalent , Reuters reported Friday, citing an unnamed person with direct knowledge of the matter.The report said that Catalent is preparing senior management for the deal to go through.The deal, crucial for boosting production of Novo Nordisk's blockbuster weight-loss drug Wegovy, awaits a final decision from the European Commission by Dec. 6.Novo Nordisk, Catalent, European Commission did not immediately respond to requests for comment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4530":"医药外包概念","NVO.AU":"NOVO RESOURCES CORP-CDI","BK4588":"碎股","BK4007":"制药","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVO":"诺和诺德","BK7104":"黄金","CTLT":"Catalent","BK4585":"ETF&股票定投概念","BK4156":"煤与消费用燃料","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"市场热议：Novo Holdings将获得欧盟批准以165亿美元收购Catalent","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTLT":1,"NVO.AU":1,"NVO":0.9},"content_text":"Novo Nordisk's (NVO) parent company, Novo Holdings, is expected to win EU antitrust approval for its pending $16.5 billion acquisition of US contract drug maker Catalent (CTLT), Reuters reported Friday, citing an unnamed person with direct knowledge of the matter.The report said that Catalent is preparing senior management for the deal to go through.The deal, crucial for boosting production of Novo Nordisk's blockbuster weight-loss drug Wegovy, awaits a final decision from the European Commission by Dec. 6.Novo Nordisk, Catalent, European Commission did not immediately respond to requests for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486086997"}